Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Amortizatization of Intangibles (2022 - 2025)

Zentalis Pharmaceuticals (ZNTL) has 4 years of Amortizatization of Intangibles data on record, last reported at $517000.0 in Q3 2025.

  • For Q3 2025, Amortizatization of Intangibles fell 68.57% year-over-year to $517000.0; the TTM value through Sep 2025 reached $3.7 million, down 66.59%, while the annual FY2024 figure was $8.0 million, 39.18% down from the prior year.
  • Amortizatization of Intangibles reached $517000.0 in Q3 2025 per ZNTL's latest filing, down from $781000.0 in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $4.6 million in Q4 2023 and bottomed at -$146000.0 in Q1 2022.
  • Average Amortizatization of Intangibles over 4 years is $1.8 million, with a median of $1.6 million recorded in 2024.
  • Peak YoY movement for Amortizatization of Intangibles: soared 2397.67% in 2023, then plummeted 69.33% in 2024.
  • A 4-year view of Amortizatization of Intangibles shows it stood at $2.5 million in 2022, then soared by 83.97% to $4.6 million in 2023, then tumbled by 69.33% to $1.4 million in 2024, then plummeted by 62.99% to $517000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Amortizatization of Intangibles were $517000.0 in Q3 2025, $781000.0 in Q2 2025, and $1.0 million in Q1 2025.